Prevalence, regional distribution, and trends of antimicrobial resistance among female outpatients with urine Klebsiella spp. isolates: a multicenter evaluation in the United States between 2011 and 2019

Abstract

Background Antimicrobial resistance research in uncomplicated urinary tract infection typically focuses on the main causative pathogen, Escherichia coli; however, little is known about the antimicrobial resistance burden of Klebsiella species, which can also cause uncomplicated urinary tract infections. This retrospective cohort study assessed the prevalence and geographic distribution of antimicrobial resistance among Klebsiella species and antimicrobial resistance trends for K. pneumoniae in the United States (2011–2019). Methods K. pneumoniae and K. oxytoca urine isolates (30-day, non-duplicate) among female outpatients (aged ≥ 12 years) with presumed uUTI at 304 centers in the United States were classified by resistance phenotype(s): not susceptible to nitrofurantoin, trimethoprim/sulfamethoxazole, or fluoroquinolone, extended-spectrum β-lactamase-positive/not susceptible; and multidrug-resistant based on ≥ 2 and ≥ 3 resistance phenotypes. Antimicrobial resistance prevalence by census division and age, as well as antimicrobial resistance trends over time for Klebsiella species, were assessed using generalized estimating equations. Results 270,552 Klebsiella species isolates were evaluated (250,719 K. pneumoniae; 19,833 K. oxytoca). The most frequent resistance phenotypes in 2019 were nitrofurantoin not susceptible (Klebsiella species: 54.0%; K. pneumoniae: 57.3%; K. oxytoca: 15.1%) and trimethoprim/sulfamethoxazole not susceptible (Klebsiella species: 10.4%; K. pneumoniae: 10.6%; K. oxytoca: 8.6%). Extended-spectrum β-lactamase-positive/not susceptible prevalence was 5.4%, 5.3%, and 6.8%, respectively. K. pneumoniae resistance phenotype prevalence varied (p < 0.0001) geographically and by age, and increased over time (except for the nitrofurantoin not susceptible phenotype, which was stable and > 50% throughout). Conclusions There is a high antimicrobial resistance prevalence and increasing antimicrobial resistance trends among K. pneumoniae isolates from female outpatients in the United States with presumed uncomplicated urinary tract infection. Awareness of K. pneumoniae antimicrobial resistance helps to optimize empiric uncomplicated urinary tract infection treatment.

Co-resistance Among Escherichia coli and Klebsiella pneumoniae Urine Isolates from Female Outpatients with Presumed UTI: A Retrospective US Cohort Study

“…This study adds to our previous findings regarding AMR prevalence among E. coli and Klebsiella species ( Klebsiella spp.) isolates in the US [ 11 , 13 ]. The current study also provides much-needed multicenter AMR surveillance data and highlights the importance of assessing patterns of co-resistance among uropathogens causing community-acquired UTIs.…”

“…Indeed, we previously reported that 14.4 and 3.8% of E. coli isolates have ≥ 2 and ≥ 3 drug resistance phenotypes, respectively [ 11 ], while more than 10% of Klebsiella spp. and K. pneumoniae isolates have ≥ 2 drug resistance phenotypes [ 13 ], but these new analyses of co-resistance among resistant isolates highlight the limitations of the currently available uUTI antibiotics. Raising awareness of antimicrobial co-resistance phenotypes should help inform empiric treatment decisions.…”

Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens

“…Klebsiella pneumoniae is considered to be one of the most important opportunistic pathogens responsible for NIs including sepsis, soft tissue infections, pneumonia [168], and UTIs, which are the most common worldwide [169]. K. pneumoniae is implicated in 6-17% of opportunistic UTI cases mainly linked to bacterial adhesion in the inner and outer surfaces of the urinary catheter [170,171]. Moreover, it is the second pathogen involved in BSIs, after E. coli [172].…”